ECM
OCRX

Endurant Capital Management’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Endurant Capital Management’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-120,942
Closed -$140K – 109
2017
Q2 		$140K Sell
120,942
-31,700
-21% -$36.8K 0.04% 92
2017
Q1 		$200K Sell
152,642
-73,800
-33% -$94K 0.06% 88
2016
Q4 		$476K Buy
226,442
+123,300
+120% +$288K 0.2% 63
2016
Q3 		$272K Hold
103,142
– – 0.1% 92
2016
Q2 		$196K Sell
103,142
-33,951
-25% -$89.3K 0.07% 87
2016
Q1 		$403K Hold
137,093
– – 0.13% 75
2015
Q4 		$428K Sell
137,093
-40,028
-23% -$137K 0.14% 72
2015
Q3 		$560K Sell
177,121
-54,020
-23% -$208K 0.19% 66
2015
Q2 		$878K Buy
231,141
+71,939
+45% +$276K 0.26% 67
2015
Q1 		$750K Sell
159,202
-51,077
-24% -$294K 0.25% 77
2014
Q4 		$1.34M Buy
+210,279
New +$1.23M 0.53% 52

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Endurant Capital Management's OCRX Position: Q3 2017 in Review

Endurant Capital Management sold out of Ocera Therapeutics, Inc. (OCRX) in Q3 2017, closing a stake of 120,942 shares — an estimated $140K sold.

Endurant Capital Management first reported a position in OCRX in Q4 2014 and held it in 11 quarters. The position peaked at $1.34M in Q4 2014. 21 funds tracked by Wall St. Rank hold OCRX as of Q3 2017.

  • Endurant Capital Management reported no remaining Ocera Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Endurant Capital Management sold 120,942 Ocera Therapeutics, Inc. shares in Q3 2017, an estimated $140K.
  • Endurant Capital Management first reported a position in Ocera Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Endurant Capital Management's Ocera Therapeutics, Inc. position peaked at $1.34M in Q4 2014.
  • 21 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q3 2017.

Based on Endurant Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.